{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:19:13Z","timestamp":1776255553675,"version":"3.50.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sex-based differences influence tumor biology, immune responses, and treatment outcomes in renal cell carcinoma (RCC), yet most computational models do not jointly incorporate sex hormones, immune composition, and tumor genetic evolution. Agent-based models (ABMs) effectively simulate tumor\u2013immune interactions but are rarely extended to include sex-specific modulation or machine learning\u2013based optimization. This study enhanced an agent-based learning model (ALM) to simulate RCC progression and treatment response by integrating hormonal effects, immune interactions, and tumor genetic adaptation with data-driven tuning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      An RCC-specific ALM was developed incorporating immune agents (CD8+, NK, Treg, dendritic cells), hormone-sensitive mechanisms, tumor genetic modules, and effects of immune checkpoint inhibitors (\n                      <jats:italic>ICI<\/jats:italic>\n                      s) and tyrosine kinase inhibitors (\n                      <jats:italic>TKI<\/jats:italic>\n                      s). Tumor evolution was modeled using a genetic algorithm simulating promoter and gene mutations, with fitness defined by immune evasion and proliferation advantages. Model parameters were optimized using clinical outcomes from the ARON dataset via the Optuna framework, and performance was assessed using concordance index (\n                      <jats:italic>CI<\/jats:italic>\n                      ) and mean squared error (\n                      <jats:italic>MSE<\/jats:italic>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Simulations reproduced sex-specific treatment responses. Female models showed delayed initial responses but stronger late immune activation and rapid tumor regression, whereas male models exhibited more stable early responses but greater tumor resilience driven by genetic adaptations. Adaptive learning showed capability of reducing prediction error with both fitness functions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This ALM offers an exploratory framework to provide preliminary insights into how sex hormones, immune dynamics, and tumor genetics may jointly contribute to shaping RCC treatment outcomes. Although the limited sample size constrains validation, the results suggest the potential of combining ABMs with biological data-driven optimization to support patient prediction and call for further investigation in larger cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1779638","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:43:15Z","timestamp":1775054595000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["An agent-based learning model integrating sex differences in renal cell carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Emanuela","family":"Merelli","sequence":"first","affiliation":[{"name":"School of Sciences and Technology, University of Camerino","place":["Camerino, MC, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Taha","sequence":"additional","affiliation":[{"name":"Royal Marsden NHS Foundation Trust","place":["London, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Caputo","sequence":"additional","affiliation":[{"name":"School of Sciences and Technology, University of Camerino","place":["Camerino, MC, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Destiny","family":"Obude","sequence":"additional","affiliation":[{"name":"School of Sciences and Technology, University of Camerino","place":["Camerino, MC, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Papa","sequence":"additional","affiliation":[{"name":"School of Sciences and Technology, University of Camerino","place":["Camerino, MC, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Tumori \u201cGiovanni Paolo II\u201d","place":["Bari, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, University Hospital of Parma","place":["Parma, Italy"]},{"name":"Department of Medicine and Surgery, University of Parma","place":["Parma, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[{"name":"Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]},{"name":"Department of Medical and Surgical Sciences (DIMEC), University of Bologna","place":["Bologna, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Molina-Cerrillo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Ram\u00f3n y Cajal","place":["Madrid, Spain"]},{"name":"ARON Research Foundation Ente del Terzo Settore (ETS)","place":["Macerata, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Sabino Marques","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group - LACOG","place":["Porto Alegre, Brazil"]},{"name":"Oncology and Hematology Department, Hospital S\u00edrio Liban\u00eas","place":["Bras\u00edlia, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigida Anna","family":"Maiorano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Hospital","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[{"name":"ARON Research Foundation Ente del Terzo Settore (ETS)","place":["Macerata, Italy"]},{"name":"Medical Oncology Unit, Macerata Hospital","place":["Macerata, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104002","article-title":"Sex differences in the pharmacokinetics of anticancer drugs: a systematic review","volume":"9","author":"Delahousse","year":"2024","journal-title":"ESMO Open"},{"key":"B2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00262-024-03719-0","article-title":"Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations","volume":"73","author":"Incorvaia","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01184","article-title":"Influence of androgens on immunity to self and foreign: effects on immunity and cancer","volume":"11","author":"Ben-Batalla","year":"2020","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-03848-7","article-title":"Impact of comorbidity on survival in cancer patients receiving immune checkpoint inhibitors","volume":"27","author":"Yal\u00e7\u0131ner","year":"2025","journal-title":"J Clin Transl Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.10.008","article-title":"Sex hormone signaling and regulation of immune function","volume":"56","author":"Hoffmann","year":"2023","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-1736","article-title":"Estrogen receptor and immune checkpoint inhibitors: new partners in lung cancer","volume":"29","author":"Valencia","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076302","article-title":"Gender-specific impact of sex hormones on the immune system","volume":"24","author":"Sciarra","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41419-022-04956-w","article-title":"High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR\/circFKBP5\/miRNA-513a-5p\/PD-L1 signals","volume":"13","author":"Tang","year":"2022","journal-title":"Cell Death Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184588","article-title":"Sex and gender differences in kidney cancer: clinical and experimental evidence","volume":"13","author":"Peired","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056667","article-title":"Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-\u03b2 activation","volume":"8","author":"Yu","year":"2013","journal-title":"PLoS One"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01616-1","article-title":"Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR","volume":"40","author":"You","year":"2021","journal-title":"Oncogene"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.517","article-title":"Investigating prostate cancer tumour-stroma interactions: clinical and biological insights from an evolutionary game","volume":"106","author":"Basanta","year":"2012","journal-title":"Br J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.642760","article-title":"Agent-based learning model for the obesity paradox in RCC","volume":"9","author":"Belenchia","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2022.10.006","article-title":"Agent-based methods facilitate integrative science in cancer","volume":"33","author":"West","year":"2023","journal-title":"Trends Cell Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1371\/journal.pcbi.1005991","article-title":"PhysiCell: an open source physics-based cell simulator for 3-D multicellular systems","volume":"14","author":"Ghaffarizadeh","year":"2018","journal-title":"PLoS Comput Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-024-00472-z","article-title":"A multiscale model of immune surveillance in micrometastases gives insights on cancer patient digital twins","volume":"10","author":"Rocha","year":"2024","journal-title":"Syst Biol Appl"},{"key":"B18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2025.06.048","article-title":"Human interpretable grammar encodes multicellular systems biology models to democratize virtual cell laboratories","volume":"188","author":"JJohnson","year":"2025","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jtbi.2009.03.005","article-title":"Evolution of cell motility in an individual-based model of tumour growth","volume":"259","author":"Gerlee","year":"2009","journal-title":"J Theor Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-0368","article-title":"Spatial heterogeneity of immune regulators drives dynamic changes in local immune responses, affecting disease outcomes in pancreatic cancer","volume":"30","author":"Karamitopoulou","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-023-01430-8","article-title":"Novel strategies for cancer immunotherapy: counter-immunoediting therapy","volume":"16","author":"Liu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/sysbio\/syw077","article-title":"Fundamentals and recent developments in approximate Bayesian computation","volume":"66","author":"Lintusaari","year":"2017","journal-title":"Syst Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmgm.2020.107576","article-title":"Visualising 2-simplex formation in metabolic reactions","volume":"97","author":"Piangerelli","year":"2020","journal-title":"J Mol Graph Mod"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076736","article-title":"Interferons and resistance mechanisms in tumors and pathogen-driven diseases-focus on the major histocompatibility complex (MHC) antigen processing pathway","volume":"24","author":"Massa","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000319","article-title":"Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma","volume":"8","author":"Labriola","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/jcp-2023-208848","article-title":"Effect of CD274 (PD-L1) overexpression on survival outcomes in 10 specific cancers: a systematic review and meta-analysis","volume":"76","author":"Park","year":"2023","journal-title":"J Clin Pathol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/gcc.22893","article-title":"Pathogenic germline variants in patients with features of hereditary renal cell carcinoma: evidence for further locus heterogeneity","volume":"60","author":"Smith","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235733","article-title":"The underestimated role of the p53 pathway in renal cancer","volume":"14","author":"Amendolare","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinsp.2023.100259","article-title":"Gene mutation profiling and clinical significances in patients with renal cell carcinoma","volume":"78","author":"Wang","year":"2023","journal-title":"Clinics (Sao Paulo)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s12672-025-04106-6","article-title":"Clinical value and mechanism of CDKN2A in clear cell renal cell carcinoma","volume":"16","author":"Li","year":"2025","journal-title":"Discov Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"11848","DOI":"10.1038\/s41598-023-38681-x","article-title":"Stage-specific coexpression network analysis of Myc in cohorts of renal cancer","volume":"13","author":"Priyam","year":"2023","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000002442","article-title":"Renal tumorigenesis via RAS\/RAF\/MAPK pathway alterations beyond papillary renal neoplasm with reverse polarity","volume":"49","author":"Kwon","year":"2025","journal-title":"Am J Surg Pathol"},{"key":"B33","first-page":"71","article-title":"EGFR kinase-dependent and kinase-independent roles in clear cell renal cell carcinoma","volume":"6","author":"Cossu-Rocca","year":"2015","journal-title":"Am J Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2012.727","article-title":"HER2 expression in renal cell carcinoma is rare and negatively correlated with that in normal renal tissue","volume":"4","author":"Wang","year":"2012","journal-title":"Oncol Lett"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres","article-title":"Genetic analysis reveals the important role of the APC gene in clear cell renal cell carcinoma","volume":"41","author":"Lai","year":"2021","journal-title":"Anticancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164245","article-title":"Identification and targeting of mutant peptide neoantigens in cancer immunotherapy","volume":"13","author":"Verdon","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3233\/KCA-230006","article-title":"Antigenic targets in clear cell renal cell carcinoma","volume":"7","author":"Schindler","year":"2023","journal-title":"Kidney Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00978-2","article-title":"Global real-world outcomes of patients receiving immuno-oncology combinations for advanced renal cell carcinoma: the ARON-1 study","volume":"18","author":"Santoni","year":"2023","journal-title":"Target Oncol"},{"key":"B39","article-title":"Optuna: a nextgeneration hyperparameter optimization framework","author":"Akiba","year":"2019"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.18632\/aging.203100","article-title":"Sex-related differences in the efficacy of immune checkpoint inhibitors in Malignancy: a systematic review and meta-analysis","volume":"13","author":"Lai","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-03894-1","article-title":"Sex and gender differences in cancer pathogenesis and pharmacology","volume":"27","author":"Bernardez","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.33696\/cancerimmunol.7.102","article-title":"Sexual dimorphism in immunity and metabolism: unraveling the impact on response to cancer immunotherapy","volume":"7","author":"Soloff","year":"2025","journal-title":"J Cancer Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071054","article-title":"Sex-related differences in immunotherapy toxicities: insights into dimorphic responses","volume":"17","author":"Canzian","year":"2025","journal-title":"Cancers"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2024.2344600","article-title":"Agent-based modeling in cancer biomedicine: applications and tools for calibration and validation","volume":"25","author":"Cogno","year":"2024","journal-title":"Cancer Biol Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00262-024-03876-2","article-title":"Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma","volume":"74","author":"Ishihara","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B46","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13293-023-00540-9","article-title":"Sex differences in renal cell carcinoma: a single-cell analysis reveals exhausted CD8+ T-cells highly infiltrated in males","volume":"14","author":"Ning","year":"2023","journal-title":"Biol Sex Differ"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.immuni.2022.05.012","article-title":"Androgen receptor\u2013mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity","volume":"55","author":"Yang","year":"2022","journal-title":"Immunity"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq2630","article-title":"Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer","volume":"7","author":"Kwon","year":"2022","journal-title":"Sci Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241269664","article-title":"The influence of sex hormones on renal cell carcinoma","volume":"16","author":"Ladurner","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-97163-4","article-title":"Regulatory mechanism and prognostic value of sex hormone pathways connected with metabolism and immune signaling in clear cell renal cell carcinoma","volume":"15","author":"Geng","year":"2025","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.artmed.2024.102884","article-title":"Agent-based approaches for biological modeling in oncology: a literature review","volume":"152","author":"Stephan","year":"2024","journal-title":"Artif Intell Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.122.001571","article-title":"Agent-based modelling reveals the role of the tumor microenvironment on the short-term success of combination temozolomide\/immune checkpoint blockade to treat glioblastoma","volume":"386","author":"Surendran","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1583421","article-title":"Sex-specific cytokine signatures as predictors of anti-PD1 therapy response in non-small cell lung cancer","volume":"16","author":"Taylor","year":"2025","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1109\/TCBB.2012.5","article-title":"Multilevel computational modeling and quantitative analysis of bone remodeling","volume":"9","author":"Paoletti","year":"2012","journal-title":"IEEE\/ACM Trans Comput Biol Bioinf"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s11047-014-9436-7","article-title":"Topology driven modeling: the IS metaphor","volume":"14","author":"Merelli","year":"2015","journal-title":"Nat Comput"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1779638\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:35:36Z","timestamp":1776252936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1779638\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2026.1779638"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1779638","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"1779638"}}